Jackson O’Brien, Ph.D.

Back to team

Dr. O’Brien joined Lincoln Park Capital in 2021 as a biotechnology analyst. Prior to joining, he developed proof-of-principle molecular computational devices to demonstrate and understand the computational capacity of biochemical systems as a graduate researcher at the University of Chicago’s Department of Physics (M.S 2017, Ph.D 2021). During his academic career, he collaborated with interdisciplinary teams of physicists, computer scientists, and chemical/biological engineers on primary research publications and presentations at international conferences. Currently, he covers biotechnology and therapeutics broadly with an emphasis on computational methodologies. He completed a B.S. with a double major in Physics and Mathematics at Butler University in 2016, graduating summa cum laude and Phi Beta Kappa.

ALL TEAM MEMBERS

Joshua B. Scheinfeld Founder and Managing Member

Mr. Scheinfeld has over 20 years experience investing in public and private companies and since 1999 has been a founder of investment funds that have funded or committed to fund over $3.0 billion.

learn more
Jonathan I. Cope Founder and Managing Member

Mr. Cope has over 20 years experience investing in public and private companies and focuses on private equity investments and life sciences investing.

learn more
Richard C. Vogel CPA Founder and President

Mr. Vogel since 1995 has worked with investment firms, managers and groups including extensive involvement in direct investments in the public equity markets as well secondary market investments.

learn more
Robert A. Garcia Founder and CFO

Mr. Garcia brings a broad based knowledge of the private equity sector and public markets. As an investment professional since 1998, Mr. Garcia has been involved in the operational side of private equity and portfolio management in the securities industry.

learn more
Phillip J. Kerewich Vice President

Mr. Kerewich joined Lincoln Park Capital in 2011 and contributes a unique background and understanding of the capital markets for public companies. Since joining Lincoln Park Mr. Kerewich has been an integral part of the investment team, including analyzing and structuring public company investments.

learn more
Frederic J. Salchli M.S. CTO & Vice President

Mr. Salchli joined LPC in 2014 as CTO and brings a diversity of experience in business, technology and the life sciences. Mr. Salchli evaluates technology investment opportunities and advises LPC private portfolio companies and emerging startups.

learn more
Trevor L. Davis, Ph.D. Vice President, Life Sciences

Dr. Davis joined Lincoln Park Capital in 2017 as a biotechnology analyst. Prior to joining the firm, he studied how gene regulatory networks control cellular behaviors during his doctoral work at the University of Chicago. His thesis culminated in multiple primary research publications, including perspectives on the trajectory of regenerative…

learn more
Oscar Palmer, CFA Analyst

Mr. Palmer joined Lincoln Park Capital in 2015 as an Analyst. Before joining LPC, Mr. Palmer held several internship positions while attending DePaul University including as an investment intern at Saxony Capital Management, LLC an asset management firm, where he worked in portfolio analysis and client management.

learn more
Tim Hogaboom Analyst

Mr. Hogaboom joined the Lincoln Park Capital team in 2017 as an Analyst. Prior to, Mr. Hogaboom worked at Robert W. Baird on the Capital Markets Operations team assisting in Institutional Trading. While attending Marquette University, he worked as a valuation analyst intern with FV & FMV Valuation, Inc. as…

learn more
Jackson O’Brien, Ph.D. Analyst

Dr. O’Brien joined Lincoln Park Capital in 2021 as a biotechnology analyst. Prior to joining, he developed proof-of-principle molecular computational devices to demonstrate and understand the computational capacity of biochemical systems as a graduate researcher at the University of Chicago’s Department of Physics (M.S 2017, Ph.D 2021). During his academic…

learn more